IR-Surviving NSCLC Cells Exhibit Different Patterns of Molecular and Cellular Reactions Relating to the Multifraction Irradiation Regimen and p53-Family Proteins Expression

被引:12
作者
Alhaddad, Lina [1 ]
Pustovalova, Margarita [1 ,2 ]
Blokhina, Taisia [1 ,2 ,3 ]
Chuprov-Netochin, Roman [1 ]
Osipov, Andreyan N. [1 ,2 ,3 ]
Leonov, Sergey [1 ,4 ]
机构
[1] Moscow Inst Phys & Technol, Sch Biol & Med Phys, Dolgoprudnyi 141700, Russia
[2] Fed Med Biol Agcy SRC FMBC, Burnasyan Fed Med Biophys Ctr, State Res Ctr, Moscow 123098, Russia
[3] Russian Acad Sci, Semenov Inst Chem Phys, Moscow 119991, Russia
[4] Russian Acad Sci, Inst Cell Biophys, Pushchino 142290, Russia
基金
俄罗斯科学基金会;
关键词
radioresistance; non-small cell lung cancer; p53; p63; p73; FRA1; polyploid cancer cells; fractionated irradiation; BODY RADIATION-THERAPY; ANCHORAGE-INDEPENDENT GROWTH; CANCER STEM-CELLS; LUNG-CANCER; MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; P63; EXPRESSION; GIANT-CELLS; P53; RADIOTHERAPY;
D O I
10.3390/cancers13112669
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary For the first time, we demonstrated that the significant decrease in p63/p73 expression together with the absence of functional p53 could underlie an increase in the fraction of polyploid cells, transformation rates, and the glycolytic NAD(P)H production in multifraction X-ray radiation exposure (MFR)-surviving cancer cells, providing conditions for radioresistance associated with epithelial-mesenchymal transition (EMT)-like process activation. During radiation therapy (RT), the treatment dose, fractionation, and dose limits for organs at risk (OARs) do not change between patients and are still prescribed mainly based on the Tumor, Node, Metastasis (TNM) stage, performance status, and comorbidities, taking no account of the tumor biology. Our data once again emphasize that non-small cell lung cancer (NSCLC) therapy approaches should become more personalized according to RT regimen, tumor histology, and molecular status of critical proteins. Radiotherapy is a primary treatment modality for patients with unresectable non-small cell lung cancer (NSCLC). Tumor heterogeneity still poses the central question of cancer radioresistance, whether the presence of a particular cell population inside a tumor undergoing a selective outgrowth during radio- and chemotherapy give rise to metastasis and tumor recurrence. In this study, we examined the impact of two different multifraction X-ray radiation exposure (MFR) regimens, fraction dose escalation (FDE) in the split course and the conventional hypofractionation (HF), on the phenotypic and molecular signatures of four MFR-surviving NSCLC cell sublines derived from parental A549 (p53 wild-type) and H1299 (p53-null) cells, namely A549FR/A549HR, H1299FR/H1299HR cells. We demonstrate that sublines surviving different MFR regimens in a total dose of 60 Gy significantly diverge in their molecular traits related to irradiation regimen and p53 status. The observed changes regarding radiosensitivity, transformation, proliferation, metabolic activity, partial epithelial-to-mesenchymal transition (EMT) program activation and 1D confined migratory behavior (wound healing). For the first time, we demonstrated that MFR exposure led to the significant decrease in the expression of p63 and p73, the p53-family members, in p53null cells, which correlated with the increase in cell polyploidy. We could not find significant differences in FRA1 expression between parental cells and their sublines that survived after any MFR regimen regardless of p53 status. In our study, the FDE regimen probably causes partial EMT program activation in MFR-survived NSCLC cells through either Vimentin upregulation in p53null or an aberrant N-cadherin upregulation in p53wt cells. The HF regimen likely less influences the EMT activation irrespectively of the p53 status of MFR-survived NSCLC cells. Our data highlight that both MFR regimens caused overall higher cell transformation of p53null H1299FR and H1299HR cells than their parental H1299 cells. Moreover, our results indicate that the FDE regimen raised the radioresistance and transformation of MFR-surviving NSCLC cells irrespectively of their p53 status, though the HF regimen demonstrated a similar effect on p53null NSCLC cells only. Our data once again emphasize that NSCLC therapy approaches should become more personalized according to radiation therapy (RT) regimen, tumor histology, and molecular status of critical proteins.
引用
收藏
页数:20
相关论文
共 70 条
[1]   A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion [J].
Adiseshaiah, Pavan ;
Vaz, Michelle ;
Machireddy, Narsa ;
Kalvakolanu, Dhananjaya V. ;
Reddy, Sekhar P. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2008, 216 (02) :405-412
[2]   p53: Guardian of ploidy [J].
Aylon, Yael ;
Oren, Moshe .
MOLECULAR ONCOLOGY, 2011, 5 (04) :315-323
[3]   Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy [J].
Baumann, Pia ;
Nyman, Jan ;
Hoyer, Morten ;
Wennberg, Berit ;
Gagliardi, Giovanna ;
Lax, Ingmar ;
Drugge, Ninni ;
Ekberg, Lars ;
Friesland, Signe ;
Johansson, Karl-Axel ;
Lund, Jo-Asmund ;
Morhed, Elisabeth ;
Nilsson, Kristina ;
Levin, Nina ;
Paludan, Merete ;
Sederholm, Christer ;
Traberg, Anders ;
Wittgren, Lena ;
Lewensohn, Rolf .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3290-3296
[4]   p53: new roles in metabolism [J].
Bensaad, Karim ;
Vousden, Karen H. .
TRENDS IN CELL BIOLOGY, 2007, 17 (06) :286-291
[5]  
Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
[6]   Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells [J].
Boudreau, H. E. ;
Casterline, B. W. ;
Burke, D. J. ;
Leto, T. L. .
BRITISH JOURNAL OF CANCER, 2014, 110 (10) :2569-2582
[7]   STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: THE PATTERN OF FAILURE IS DISTANT [J].
Bradley, Jeffrey D. ;
El Naqa, Issam ;
Drzymala, Robert E. ;
Trovo, Marco ;
Jones, Griffin ;
Denning, Mary Dee .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (04) :1146-1150
[8]   Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume [J].
Brianzoni, E ;
Rossi, G ;
Ancidei, S ;
Berbellini, A ;
Capoccetti, F ;
Cidda, C ;
D'Avenia, P ;
Fattori, S ;
Montini, GC ;
Valentini, G ;
Proietti, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 (12) :1392-1399
[9]   Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex [J].
Brugarolas, J ;
Lei, K ;
Hurley, RL ;
Manning, BD ;
Reiling, JH ;
Hafen, E ;
Witter, LA ;
Ellisen, LW ;
Kaelin, WG .
GENES & DEVELOPMENT, 2004, 18 (23) :2893-2904
[10]   Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay - A comparative study [J].
Buch, Karl ;
Peters, Tanja ;
Nawroth, Thomas ;
Saenger, Markus ;
Schmidberger, Heinz ;
Langguth, Peter .
RADIATION ONCOLOGY, 2012, 7